Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-10-10
2011-12-13
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
08076375
ABSTRACT:
This disclosure ascribes new functions to derivatives of tetralin, anthraquinone, naphthylamine, tri-amino-pyrimidine, xanthen-3-one, and/or cinnamic acid (including, for example, NSC270718R, NSC117285R, NSC170008Y, NSC306711P, NSC119913X, NSC119915Z, NSC119911V, NSC119910U, NSC128437O, NSC125908P, NSC9600Q, or NSC13778J, each obtained from the Structure Diversity Set, National Institutes of Health, National Cancer Institute, Developmental Therapeutics Program). These compounds are shown to be effective inhibitors of viral essential protein kinases (such as poxvirus B1 and/or F10 protein kinases). Exemplary chemical structures for viral protein kinase (VPK) inhibitors are provided, as are methods of using such compounds, for instance, to inhibit VPK activity and/or poxvirus growth, and/or for the treatment of poxvirus infection. Also provided are pharmaceutical compositions including disclosed VPK inhibitors.
REFERENCES:
patent: 4073904 (1978-02-01), Fleming et al.
patent: 4082550 (1978-04-01), Yoerger
patent: 4801593 (1989-01-01), Hodson et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5977061 (1999-11-01), Holy et al.
patent: WO 2005/048928 (2005-06-01), None
Austin et al., “NIH Molecular Libraries Initiative,”Science 306:1138-1139, 2004.
Boyle and Traktman, “Members of a Novel Family of Mammalian Protein Kinases Complement the DNA-Negative Phenotype of a Vaccinia VirustsMutant Defective in the B1 Kinase,”J Virol. 78:1992-2005, 2004.
Gubser et al., “Poxvirus Genomes: a Phylogenetic Analysis,”J. Gen. Virol. 85:105-117, 2004.
Harrison et al., “Discovery of Antivirals Against Smallpox,”PNAS 101:11178-11192, 2004.
Herget et al., “Novel Chemical Class of pUL97 Protein Kinase-Specific Inhibitors with Strong Anticytomegaloviral Activity,”Antimicrob. Agents Chemother. 48:4154-4162, 2004.
McFadden, “Poxvirus Tropism,”Nat. Rev. Microbiol. 3:201-213, 2005.
Szajner et al., “Evidence for an Essential Catalytic Role of the F10 Protein Kinase in Vaccinia Virus Morphogenesis,”J. Virol. 78:257-265, 2004.
Yang et al.., Antiviral Chemotherapy Facilitates Control of Poxvirus Infections Through Inhibition of Cellular Signal Transduction,J. Clin. Invest. 115:379-387, 2005.
Schulte Roberta J.
Sefton Bartholomew M.
Klarquist & Sparkman, LLP
The Salk Institute for Biological Studies
Wang Shengjun
LandOfFree
Methods of inhibiting poxvirus growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting poxvirus growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting poxvirus growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303538